Introduction This trial evaluated the safety, biologic activity, and pharmacokinetics of
belimumab, a fully human monoclonal antibody that inhibits the biologic activity of the …

For the first time in more than 50 years, the US Food and Drug Administration has approved
a drug specifically for the treatment of systemic lupus erythematosus (SLE). This drug …

Belimumab (Benlysta®) is a fully humanized monoclonal antibody that inhibits B lymphocyte
stimulator (BLyS, also known as B cell-activating factor of the tumor necrosis factor family) …

Introduction Belimumab, an anti-B-lymphocyte-stimulator antibody, is approved for the
treatment of active, autoantibody-positive systemic lupus erythematosus (SLE). Rituximab, a …

Following the approval of belimumab, the first drug to be approved for systemic lupus
erythematosus (SLE) in over 50 years, advances in our understanding of the pathogenesis …

Systemic lupus erythematosus (SLE, lupus) is a highly complex and heterogeneous
autoimmune disease that most often afflicts women in their child-bearing years. It is …

Background Anti-BLyS treatment with the human belimumab monoclonal antibody was
shown to be a safe and effective therapeutic modality in lupus patients with active disease …

Objective To investigate predictors of response, remission, low disease activity, damage,
and drug discontinuation in patients with systemic lupus erythematosus (SLE) who were …

One challenge in caring for patients with systemic lupus erythematosus (SLE) is a paucity of
approved therapeutics for treatment of the diverse disease manifestations. In the last 60 …

Introduction Systemic lupus erythematous is an autoimmune disease with diverse clinical
features and has its development associated with a complexity of genetic, hormonal and …